PTCT PTC Therapeutics, Inc.

38.97-0.03 (-0.08%)
Close: September 20, 2019

Quote

Previous Close
$38.97
Day Range
$38.52-$39.71
52 Week Range
$27.53-$48.99
Volume
1,763,854
Avg Volume
597,586
Dividend TTM
-
Ex-Dividend Date
-

Valuation

Market Cap
$2.30B
Enterprise Value (EV)
$2.23B
PE Ratio
-
EV/EBITDA
-32.49
Price/Sales
8.70
Price/Book
6.56
PEG Ratio
-

Financials

Revenue
$264.73M
Gross Profit
$229.19M
EBITDA
-$68.56M
EPS, ttm
-$4.06
Profit Margin
-
Revenue/Employee
$512.06K
Next Earnings Date
11/11/2019 (50 days)
Debt to Equity
44%
Debt
$153.01M
Cash
$227.59M
Net Debt
-

Performance

Beta
1.60
200 Day Moving Avg
$38.49
50 Day Moving Avg
$44.29
52 Week Change
-13.67%
YTD Change
15.87%
1 Month Change
-16.12%
3 Month Change
-10.72%
6 Month Change
-1.32%
1 Year Change
-13.67%
2 Year Change
239.67%
5 Year Change
108.24%

Share Count

Shares Outstanding
59.1M
Float
56.9M
Restricted Shares
2.2M
Restricted Shares, %
3.68%

PTC Therapeutics, Inc. Company Details

Sector: Health Technology

Industry: Biotechnology

CEO: Stuart W. Peltz

Website: http://www.ptcbio.com

Description: PTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of clinically-differentiated medicines. It focuses on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The company was founded by Allan Steven Jacobson and Stuart W. Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.

Employees: 517